Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.51 |
| ▸ | LPL | P06858 | 2/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102327 | 0.95 | LPL (0.53) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL8087274 | 0.93 | LPL (0.54) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL8094372 | 0.93 | LPL (0.54) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL8102302 | 0.93 | LPL (0.54) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL3892580 | 0.89 | KAT6A (0.50) | CYP4F2CYP4A11MAP1LC3BMAP1LC3ASMN1; SMN2 | |
| SCHEMBL11757933 | 0.86 | CYP4F2 (0.54) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL8098007 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL8341269 | 0.84 | CYP4F2 (0.53) | CYP4F2CYP4A11LPLLIPGSPHK2 | |
| SCHEMBL31124111 | 0.84 | FOLH1 (0.58) | CYP4F2CYP4A11PPARGPPARASMN1; SMN2 | |
| SCHEMBL3387825 | 0.84 | FOLH1 (0.58) | CYP4F2CYP4A11PPARGPPARASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-07-04 | — | — | US | disclosed |
| CN-103119021-A | Anti-inflammatory agents | CAMBRIDGE ENTPR LTD | 2013-05-22 | — | — | CN | disclosed |
| EP-2580196-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Ltd. (GB) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154696-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-15 | — | — | WO | disclosed |
| EP-0708077-B1 | Diamino compounds and methods for preparing them | CHISSO CORP (JP) | 2000-12-27 | — | — | EP | disclosed |
| EP-0708077-A1 | Diamino compounds and methods for preparing them | CHISSO CORPORATION (JP) | 1996-04-24 | — | — | EP | disclosed |
| EP-0041711-B1 | 6-CHLORO- OR 6-BROMO-1,2-DIHYDRO-3H-PYRROLO(1,2-A)-PYRROLE-1-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4410534-A | 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4344943-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1982-08-17 | — | — | US | disclosed |
| EP-0041711-A1 | 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo(1,2-a)-pyrrole-1-carboxylic acids and derivatives thereof, process for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172318-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | CYP4F2 2847/4885CYP4A11 1529/4885LPL 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.